PubMed Health treatment related to Von Willebrand's Disease: 63
Treatment for von Willebrand disease (VWD) is based on the type of VWD you have and how severe it is. Most cases of VWD are mild, and you may need treatment only if you have surgery , tooth extraction, or an accident. Medicines are used to: Increase the amount of von Willebrand factor and factor VIII released into the bloodstream Replace von Willebrand factor Prevent the breakdown of blood clots Control heavy menstrual bleeding in women
Drugs for Von Willebrand's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 19)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
2 |
|
Arginine Vasopressin |
|
Phase 4 |
|
|
|
3 |
|
Vasopressins |
|
Phase 4 |
|
|
|
4 |
|
Coagulants |
|
Phase 4 |
|
|
|
5 |
|
Tranexamic acid |
Approved |
Phase 3 |
|
1197-18-8 |
5526 |
Synonyms:
(1R,4R)-4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID
Acide tranexamique
Acide tranéxamique
Acido tranexamico
ácido tranexámico
Acidum tranexamicum
CL-65336
CL-65336|Cyclo-F®|Cyklokapron®|Femstrual®|trans AMCHA
CYCLO-F
CYKLO-F HEAVY PERIOD RELIEF
Cyklokapron
EXACYL
FEMSTRUAL
LB1148
LB-1148
LYSTEDA
MENSTRALITE
|
NSC-291305
RP-18429
Tranexamate
Tranexamic acid
Tranexamsaeure
Tranexmate
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
trans-Tranexamate
trans-Tranexamic acid
|
|
6 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
7 |
|
Anesthetics |
|
Phase 3 |
|
|
|
8 |
|
Hemostatics |
|
Phase 3 |
|
|
|
9 |
|
Antifibrinolytic Agents |
|
Phase 3 |
|
|
|
10 |
|
Oprelvekin |
Approved, Investigational |
Phase 2 |
|
145941-26-0 |
|
Synonyms:
ADIPOGENESIS INHIBITORY FACTOR
AGIF
IL-11
Interleukin 11
Interleukin-11
|
INTERLEUKIN-11 PRECURSOR
NEUMEGA
Neumega®
OPRELVEKIN
Recombinant interleukin-11
|
|
11 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
|
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
12 |
|
Clopidogrel |
Approved |
|
|
120202-66-6, 113665-84-2 |
60606 |
Synonyms:
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
BMS Brand 1 OF clopidogrel bisulfate
BMS Brand 2 OF clopidogrel bisulfate
CLOPIDOGREL
Clopidogrel [Ban:Inn]
Clopidogrel besilate
Clopidogrel besylate
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel hydrochloride
CLOPIDOGREL HYDROGEN SULFATE
Clopidogrel mepha
Clopidogrel napadisilate
|
Clopidogrel sandoz
CLOPIDOGREL SULFATE
Clopidogrel, (+)(S)-isomer
Clopidogrel-mepha
Clopidogrelum
GREPID
Iscover
Isocover
Plavix
PLAVIX®
R 130964
R-130964
SR 25990
SR-25990
SR-25990C
|
|
13 |
|
Ticagrelor |
Approved |
|
|
274693-27-5 |
9871419 |
Synonyms:
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AR-C126532XX
AR-C126532XX|AZD6140|Brilinta®|Brilique®|compound 17 [PMID: 17827008]
AZD 6140
|
AZD6140
AZD-6140
Brilinta
Brilique
TICAGRELOR
|
|
14 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
15 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
16 |
|
Platelet Aggregation Inhibitors |
|
|
|
|
|
17 |
|
Deamino Arginine Vasopressin |
|
|
|
|
|
18 |
|
Factor VIII |
|
|
|
|
|
19 |
|
Citrate |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 81)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery |
Completed |
NCT01994330 |
Phase 4 |
desmopressin |
2 |
An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects With Von Willebrand Disease |
Completed |
NCT02552576 |
Phase 4 |
|
3 |
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease. |
Completed |
NCT00168090 |
Phase 4 |
Blood coagulation Factor VIII and vWF, human |
4 |
Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand Disease |
Recruiting |
NCT02472665 |
Phase 4 |
plasma-derived FVIII/VWF concentrate |
5 |
A Post-marketing Observational Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human), Alphanate®, in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease |
Active, not recruiting |
NCT00555555 |
Phase 4 |
|
6 |
A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE |
Completed |
NCT02973087 |
Phase 3 |
|
7 |
A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease |
Completed |
NCT02283268 |
Phase 3 |
|
8 |
An Open Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Severe Haemophilia A Patients. |
Completed |
NCT02246881 |
Phase 3 |
|
9 |
An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects With Von Willebrand Disease. |
Completed |
NCT00941616 |
Phase 2, Phase 3 |
|
10 |
An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54 |
Completed |
NCT01224808 |
Phase 3 |
|
11 |
A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects With Von Willebrand Disease |
Completed |
NCT01213446 |
Phase 3 |
|
12 |
A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease |
Completed |
NCT01410227 |
Phase 3 |
Placebo |
13 |
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With Von Willebrand Disease (VWD) |
Completed |
NCT04052698 |
Phase 3 |
Wilate |
14 |
Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures |
Completed |
NCT01365546 |
Phase 3 |
|
15 |
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD) |
Recruiting |
NCT03879135 |
Phase 3 |
|
16 |
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease |
Recruiting |
NCT02932618 |
Phase 3 |
|
17 |
Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 Years |
Recruiting |
NCT04953884 |
Phase 3 |
wilate |
18 |
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial |
Recruiting |
NCT04344860 |
Phase 3 |
Recombinant Von Willebrand factor;Tranexamic Acid Injection [Cyklokapron] |
19 |
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study |
Active, not recruiting |
NCT02606045 |
Phase 3 |
recombinant von Willebrand factor;tranexamic acid |
20 |
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Children Diagnosed With Severe Von Willebrand Disease |
Not yet recruiting |
NCT05582993 |
Phase 3 |
|
21 |
An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery |
Terminated |
NCT00404300 |
Phase 3 |
Optivate |
22 |
An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate |
Terminated |
NCT00387192 |
Phase 3 |
Optivate |
23 |
A Double-blind, Placebo-controlled Pilot Trial to Investigate the Administration of Von Willebrand Factor Concentrate (Willfact®, LFB France) in Adult Patients During Extracorporeal Membrane Oxygenation |
Unknown status |
NCT03613584 |
Phase 2 |
Von Willebrand Factor;Saline Solution |
24 |
A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders |
Completed |
NCT00632242 |
Phase 2 |
ARC1779 |
25 |
Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia |
Completed |
NCT00524342 |
Phase 2 |
Oprelvekin, Interleukin 11, IL-11 |
26 |
Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease |
Completed |
NCT00151125 |
Phase 2 |
recombinant interleukin-11 |
27 |
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP |
Completed |
NCT00994929 |
Phase 2 |
|
28 |
A Randomised, Comparative, Single Dose, Open Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Different Types of Von Willebrand Disease. |
Completed |
NCT02250508 |
Phase 2 |
|
29 |
A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders |
Completed |
NCT04677803 |
Phase 2 |
BT200 |
30 |
Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery |
Terminated |
NCT00524225 |
Phase 2 |
Neumega (Oprelvekin, Interleukin 11, IL-11) |
31 |
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B |
Withdrawn |
NCT00694785 |
Phase 2 |
ARC1779 |
32 |
Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD) |
Completed |
NCT00816660 |
Phase 1 |
|
33 |
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease |
Completed |
NCT00004667 |
Phase 1 |
von Willebrand factor |
34 |
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD) |
Recruiting |
NCT04770935 |
Phase 1 |
efanesoctocog alfa (BIVV001) |
35 |
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A |
Not yet recruiting |
NCT05500807 |
Phase 1 |
Emicizumab |
36 |
Assessing the Bleeding Severity in Type I Von Willebrand Patients Using the International Society on Thrombosis and Hemostasis Bleeding Assessment Tool ( ISTH-BAT) Questionnaire |
Unknown status |
NCT03915873 |
|
|
37 |
Latin-American Von Willebrand Disease Registry |
Unknown status |
NCT04279717 |
|
|
38 |
Von Willebrand Disease in the Netherlands - Prospective Study (WiN-Pro) |
Unknown status |
NCT03521583 |
|
|
39 |
Protocol for the Determination of Menstrual Blood Losses in Women Affected by Congenital Bleeding Disorders |
Unknown status |
NCT01261936 |
|
|
40 |
Molecular and Clinical Profile of Von Willebrand Disease (VWD) in Spain (PCM-EVW-ES). Recruitment Extension, Further Data Analysis, Improvement of Registry Platform, Diagnosis and Management of VWD Application Development |
Unknown status |
NCT02869074 |
|
|
41 |
A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt |
Unknown status |
NCT04106323 |
|
|
42 |
GLOBAL HEMOSTATIC METHODS IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE CORRELATION WITH PATIENTS' CLINICAL STATUS AND USEFULNESS FOR TREATMENT MONITORING |
Unknown status |
NCT02061033 |
|
|
43 |
Low Von Willebrand in Ireland Cohort Study |
Unknown status |
NCT03167320 |
|
|
44 |
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease |
Unknown status |
NCT03715673 |
|
|
45 |
International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease. |
Completed |
NCT01949220 |
|
|
46 |
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding |
Completed |
NCT02792205 |
|
|
47 |
Does an Acquired Von Willebrand Syndrome Influence Perioperative Blood Loss in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement? |
Completed |
NCT00805051 |
|
|
48 |
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands |
Completed |
NCT00510042 |
|
|
49 |
A Canadian, Multi-center, Prospective, Open-label, Observational, Pharmacovigilance Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) in Patients Transitioning From Treatment With Currently Available Humate-P® |
Completed |
NCT00701545 |
|
|
50 |
The VWD International Prophylaxis (VIP) Study |
Completed |
NCT00557908 |
|
VWF/FVIII products |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
antihemophilic factor, human
Antihemophilic Factor, Human Recombinant
Antihemophilic factor, porcine
ANTIHEMOPHILIC FACTOR,HUMAN,METHOD M,MONOCLONAL
|
desmopressin
Desmopressin Acetate
Factor VIII
|
|